Lizardi-Cervera J, Almeda P, Guevara L, Uribe M

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 122-130
Archivo PDF: 111.24 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997; 92: 1429-39.

2. Adams RD, Foley JM. The neurological disorder associated with liver disease. Proc Ass Res Nerv Dis 1953; 32: 198-237.

3. Sobukawa E, Sakimura K, Hoshino S, Hoshino M, Miyoshi K. Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Internal Medicine 1994; 33: 718-22.

4. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984; 2: 493-5.

5. Blei AT. Helicobacter pylori, harmful to the brain? Gut 2001; 48: 590-1.

6. Bustamante J, Rimola A, Ventura P, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.

7. Powell EE, Pender MP, Chalk JB, Parkin PJ, Strong R, Lynch S, et al. Improvement in chronic hepatocerebral degeneration following liver transplantation. Gastroenterology 1990; 98: 1079-82.

8. Plauth M, Merli M, Kondrup J. Management of hepatic encephalopathy. N Eng J Med 1997; 337: 1921-2.

9. Plauth M, Merli M, Weimann A, Ferenci P, Mueller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clinical Nutrition 1997; 16: 43-55.

10. Felipo V, Miñana D, Grisolia S. Control of urea synthesis and ammonia utilization in protein deprivation and refeeding. Arch Biochem Biophys 1991; 285: 351-6.

11. Vilstrup H. Synthesis of urea after stimulation with amino acids: relation to liver function. Gut 1980; 21: 990-5.

12. Lockwood AH, McDonald JM, Rieman RE, Gelbard AS, Laughlin JS, Duffy TE, et al. The dynamics of ammonia metabolism in men. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.

13. Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279-87.

14. Bianchi GP, Marchesini G, Fabbri A, Rondelli A, Bugianesi E, Zoli M, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993; 233: 385-92.

15. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein- controlled trial. J Hepatol 1990; 11: 92-101.

16. Morgan MY. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies. J Hepatol 1990; 11: 133-41.

17. Weber FL, Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982; 82: 213-7.

18. Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987; 4: 236-44.

19. Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G, et al. Association lactulose-neomycine versus placebo dans le traitement de l’encephalopathie hepatique aigue. Resultats d’un essai controle randomise. Gastroenterol Clin Biol 1994; 18: 1063-8.

20. van Berlo CL, van Leeuwen PA, Soeters PB. Porcine intestinal ammonia liberation. Influence of food intake, lactulose and neomycin. J Hepatol 1988; 7: 250-7.

21. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406.

22. Morgan MY, Jakobovits AW, James IM, Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980; 78: 663-70.

23. Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640-4.

24. Uribe M, Farca A, Marquez MA. Treatment of chronic portal systemic encephalopathy with bromocriptine: A double blind controlled trial. Gastroenterology 1979; 76: 1347-51.

25. Uribe M, Campollo A, Vargas F. Acidifying enemas (lactitol and lactosa) vs non acidifying enemas (tap water)to treat acute portal systemic encephalopathy: A double blind randomized clinical trial. Hepatology 1987; 7: 639-43.

26. Uribe M, Berthier JM, Lewis H. Lactosa enemas plus placebo tablets vs neomycin tablets plus starch enemas in acute portal systemic ecephalopathy. A double blind randomized controlled study. Gastroenterology 1981; 81:101-6

27. Uribe M, Morán S, Poo JL, Muñoz R. In Vitro and in Vivo Lactose and Lactulose. Effects on Colonic Fermentation and Portal-systemic Encephalopathy Parameters. Scand J Gastroenterol 1997; 32 Suppl 222: 49-52.

28. Blei T. Andres. Hepatic Encephalopathy. In Complication on Cirrhosis: Pathogenesis, Consequences and Therapy. AASLD. Liver Meeting 2001; 131-134.

29. Uribe M, Morán S, Poo JL, Méndez-Sánchez N, Guevara L, García-Ramos G. Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. Scand J Gastroenterol 1998; 33: 1099-106.

30. Hepatic encephalopathy- Definition, nomenclature, diagnosis and quantification: Final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.

31. Mullen KD. Treatment of Hepatorenal syndrome. Lessons from the MARS trial. Hepatology 2002; 35(2): 492-93.